An AIM2 inflammasome biomimetic mineralization inhibitor for vascular dementia therapy
Year: 2025
Type: article
Abstract: : Integrating clinical bioinformatics with computational drug design, this study establishes a translational paradigm for nanomaterial development. M2exo@HMPB serves not only as an AIM2 inflammasome-targeting biomimetic mineralization inhibitor for VaD therapy but also provides new insights for treating AIM2-mediated cell death pathologies.
Source: Theranostics
DOI: 10.7150/thno.110389
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,671
OpenAlex ID: W4411195547